Navigation Links
Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
Date:4/10/2012

BEER-SHEVA, ISRAEL, April 10, 2012 BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

Lauren Sciences will develop the technology as a platform for treating a variety of diseases that affect the central nervous system (CNS), including Parkinson's, Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), as well as brain malignancies.

V-Smart technology is based on nanovesicles made of proprietary building blocks that provide high stability, large encapsulation capacity, targeting to specific cells and tissues, a controlled release mechanism, and passage through biological barriers, including the blood brain barrier (BBB). The V-SmartTM technology pinpoints where the drug will be released in the brain, increasing efficacy and reducing adverse effects.

It was developed by BGU researchers Dr. Sarina Grinberg of the Department of Chemistry, Dr. Charles Linder of the Department of Biotechnology and Department of Clinical Biochemistry Prof. Eliahu Heldman, who also serves as Lauren Science's chief scientific officer. Lauren Sciences will continue to conduct development activities at BGU.

"Our pre-clinical studies demonstrate that novel, nano-sized V-Smart vesicles encapsulate small molecules, peptides, proteins and nucleic acids, cross the BBB and release their encapsulated contents in the brain," said Prof. Heldman. "Our goal is to target, protect and restore dopaminergic neurons (nerve cells) in the brain that deteriorate during the course of Parkinson's disease. The success of this project should improve Parkinson's patients' lives."

The BBB is permeable for small molecules; however, an active drug delivery transport system is required for other substances. There is currently an unmet need and a great medical challenge for a safe, effective and reliable drug delivery transport system to deliver viable chemotherapeutic agents to the brain of patients with brain cancer or other CNS related clinical states.

The V-Smart platform is protected by several worldwide patents filed by BGN Technologies. Lauren Sciences was recently awarded a grant from the Michael J. Fox Foundation to develop a V-Smart therapeutic for Parkinson's disease.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia
2. Ben-Gurion University of the Negev to host
3. Ben-Gurion University of the Negev researchers develop new reversible, green window technology
4. Ben-Gurion University engineers develop technique to help combat nuclear proliferation
5. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
6. Ben-Gurion University research and technology used in new solar energy farm
7. Ben-Gurion U. researchers reveal connection between cancer and human evolution
8. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
9. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
10. Ben-Gurion University of the Negev technology being developed for use in Jordan desalination plant
11. Ben-Gurion University Alzheimers researcher demonstrates specific immune response to vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... 2016 , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of ... States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete ... on to say that, “We expect interest to continue to rise as AxioMed completes ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... , Dec. 8, 2016  Biotheranostics today ... the role of the Breast Cancer Index (BCI) ... breast cancer are most at-risk for disease recurrence ... include results from three studies advancing the understanding ... related to tumor biology and inform decisions related ...
Breaking Biology Technology: